Ep. 163 - EU Pharma Law Overhaul, Abortion Drug Ruling, Dunn's Departure
BioCentury This Week
English - February 28, 2023 00:00 - 24 minutes - 17.1 MB - ★★★★★ - 11 ratingsScience biotech biopharma pharmaceutical research investment dealmaking Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Previous Episode: Ep. 162 - New CMS Payment Models, China Markets Outlook, & Zhang's Latest Start-Up
Next Episode: Ep. 164 - Viehbacher’s Vision, NK Cells & Bat Biotech
Leaked drafts of legislation overhauling Europe’s pharmaceutical laws are causing consternation at biopharma companies. BioCentury’s editors discuss how the revised framework could cut IP protections and why any benefits from the legislation are not sufficient to attract investment to Europe. They also discuss the potential implications of an imminent ruling in a Texas lawsuit challenging FDA’s approval of abortion drug mifepristone, and comment on the departure of FDA’s Billy Dunn.